At a glance
What is it—and why does it matter?
An introduction is not yet available. The findings below address specific research questions, not a complete account of this peptide.
This published profile is a reference in progress. Findings retain their source context; missing topics are marked below.
What is it?
A molecule, not a product name.
This profile does not yet contain a published summary for this topic. This is a coverage gap, not evidence that no research exists.
How does it work?
Target, response, and disposition.
This profile does not yet contain a published summary for this topic. This is a coverage gap, not evidence that no research exists.
What has been studied?
What the evidence says.
Comparative evidence
The methods state that the systematic search and screening process resulted in inclusion of three studies.
- Reported result
- 3 studies
- Source records
- 1
- Independent studies
- 1
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“A total of three studies were included after final screening.”
Efficacy and Safety of Cerebrolysin as an Adjunct to Mechanical Thrombectomy in Acute Ischemic Stroke: A Systematic Review and Meta-Analysis of Observational Studies. · METHODS
pubmed:41880098:761cd8f60fdd:761cd8f60fdd
Comparative evidence
Study grouping in the meta-analysis is described as cerebrolysin adjunct to mechanical thrombectomy versus mechanical thrombectomy alone, across three observational studies totaling 294 patients.
- Reported result
- Total 294; 148 Cerebrolysin + MT vs 146 MT
- Source records
- 1
- Independent studies
- 1
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“This meta-analysis pooled data from three observational studies involving a total of 294 patients; 148 were treated with Cerebrolysin in combination with mechanical thrombectomy (Cerebrolysin + MT group), and 146 were treated with mechanical thrombectomy alone (MT group).”
Efficacy and Safety of Cerebrolysin as an Adjunct to Mechanical Thrombectomy in Acute Ischemic Stroke: A Systematic Review and Meta-Analysis of Observational Studies. · RESULTS
pubmed:41880098:761cd8f60fdd:761cd8f60fdd
Comparative evidence
Cerebrolysin is presented as an adjunctive (add-on) therapy used alongside reperfusion therapy in acute ischemic stroke (AIS).
- Source records
- 1
- Independent studies
- 1
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“This article provides perspectives on the use of Cerebrolysin as an adjunct treatment to reperfusion therapy in acute ischemic stroke (AIS).”
Cerebroprotection in acute ischemic stroke: Perspectives on combining cerebrolysin with recanalization therapy. · Abstract
pubmed:41349847:c82d6f422c19:c82d6f422c19
Study findings
The conclusion explicitly notes that the evidence base is limited (three observational studies, small sample sizes), which constrains certainty and external validity.
- Reported result
- only three observational studies with small sample sizes
- Source records
- 1
- Independent studies
- 1
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“Nonetheless, these conclusions are derived from only three observational studies with small sample sizes, which limits the robustness and generalizability of the findings.”
Efficacy and Safety of Cerebrolysin as an Adjunct to Mechanical Thrombectomy in Acute Ischemic Stroke: A Systematic Review and Meta-Analysis of Observational Studies. · CONCLUSION
pubmed:41880098:761cd8f60fdd:761cd8f60fdd
Risks and interactions
Risks, organized for scanning.
This profile does not yet contain a published summary for this topic. This is a coverage gap, not evidence that no research exists.
Products and regulatory status
Same ingredient. Different records.
This profile does not yet contain a published summary for this topic. This is a coverage gap, not evidence that no research exists.
Administration context
The practical clinical context.
This profile does not yet contain a published summary for this topic. This is a coverage gap, not evidence that no research exists.
Research status + gaps
What still needs better answers?
- No publishable claim yet for: administration, contraindication, identity, interaction, mechanism, regulatory, safety
- 298 compiled claim(s) withheld by automated assurance: assurance_score_below_0.58 (197), assurance_score_below_0.72 (95), current_regulatory_source_required (62), extraction_ambiguity (225), high_risk_requires_regulatory_or_two_independent_sources (100), no_direct_support (292), proposal_not_staged (1)
- A source-backed introductory overview is not yet available.
These are the limits of this profile, not an exhaustive list of scientific uncertainties.
References + discovery
Open the records yourself.
- Cerebroprotection in acute ischemic stroke: Perspectives on combining cerebrolysin with recanalization therapy. ↗
pubmed · published 2026-01-01 · retrieved 2026-09-03T08:51:04Z
- Efficacy and Safety of Cerebrolysin as an Adjunct to Mechanical Thrombectomy in Acute Ischemic Stroke: A Systematic Review and Meta-Analysis of Observational Studies. ↗
pubmed · published 2026-03-01 · retrieved 2026-09-03T08:51:04Z
Publication history and provenance
Version 1 · Automated assessment · 2026-09-03T08:51:04Z
6baa28f5b1fe2b331886b7a9c60256898748ad29406180c032424c99df27b672